| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£17,585,328 |
| Nicolas Loebel |
3,538,991 |
£398,136 |
| Junaid Bajwa |
1,193,697 |
£134,291 |
| Jean Duvall |
1,163,529 |
£130,897 |
| Jean Charest |
353,356 |
£39,753 |
| Carolyn Cross |
119,258,222 |
£13,416,550 |
| M&G Plc |
67,254,901 |
£7,566,176 |
| hInsight-NX, LLC |
42,272,654 |
£4,755,674 |
| Robert Cross |
37,772,652 |
£4,249,423 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,699,412 |
| CRUX Asset Management |
9,298,090 |
£1,046,035 |
| Chelverton Asset Management |
7,957,311 |
£895,198 |
| 14:31 |
1,327 @ 11.15p |
| 13:32 |
17 @ 11.50p |
| 13:32 |
11 @ 11.00p |
| 13:32 |
87 @ 11.50p |
| 13:32 |
25 @ 11.00p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research